Eyeworld

F RI DAY, A PRI L 25, 2 025 Los Angeles Convention Center Room 515A Registration and Lunch: 11:30 a.m. Program: 12:00 p.m.–1:00 p.m. This program is non-CME. REGISTER TODAY! Meetings.EyeWorld.org/Glaukos Empowering Interventional Glaucoma Care: The Innovative Role of iDose TR and iStent infinite in the Modern Comprehensive Practice Sponsored by Glaukos is a registered trademark of Glaukos Corporation. All rights reserved. © 2025 PM-US-2647-Rev 2 Join your peers to learn about iDose TR, including new real-world data, pioneer practice insights on interventional glaucoma, and pearls to implement into your practice. iDose TR is a long duration intracameral procedural pharmaceutical that delivers PGA therapy for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension. INDICATIONS AND USAGE iDose TR (travoprost intracameral implant) 75 mcg is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hyper tension (OHT). IMPORTANT SAFETY INFORMATION DOSAGE AND ADMINISTRATION: For ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions. CONTRADICTIONS: iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch's Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet's Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product. WARNINGS AND PRECAUTIONS: iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to con rm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent. ADVERSE REACTIONS: In controlled studies, the most common ocular adverse reactions repor ted in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity. Please see full Prescribing Information at https://www.idosetrhcp.com/. You are encouraged to repor t all side effects to the FDA. Visit www.fda. gov/medwatch or call 1-800-FDA-1088. You may also call Glaukos at 1-888-404-1644. iDose TR is MRI Conditional. Patients should be informed that the implant is MRI Conditional (as noted on their Patient ID card), and that if the patient needs to undergo an MRI, they should inform their doctor that they have an iDose TR implanted in their eye. INDICATION FOR USE. The iStent infinite® Trabecular Micro-Bypass System Model iS3 is an implantable device intended to reduce the intraocular pressure (IOP) of the eye. It is indicated for use in adult patients with primary open-angle glaucoma in whom previous medical and surgical treatment has failed. CONTRAINDICATIONS. The iStent infinite is contraindicated in eyes with angle-closure glaucoma where the angle has not been surgically opened, acute traumatic, malignant, active uveitic, or active neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure. WARNINGS. Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization that could lead to improper placement of the stent and pose a hazard. MRI INFORMATION. The iStent infinite is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details. PRECAUTIONS. The surgeon should monitor the patient postoperatively for proper maintenance of IOP. Three out of 61 par ticipants (4.9%) in the pivotal clinical trial were phakic. Therefore, there is insufficient evidence to determine whether the clinical performance of the device may be different in those who are phakic versus in those who are pseudophakic. ADVERSE EVENTS. The most common postoperative adverse events repor ted in the iStent infinite pivotal trial included IOP increase ≥ 10 mmHg vs. baseline IOP (8.2%), loss of BSCVA ≥ 2 lines (11.5%), ocular surface disease (11.5%), perioperative inflammation (6.6%) and visual field loss ≥ 2.5 dB (6.6%). CAUTION: Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events. Ike Ahmed, MD John Berdahl, MD Christine Funke, MD Mark Gallardo, MD Blake Williamson, MD FAC U LT Y

• Cover